EA201991456A1 - Bruton Imidazopyrazine Tyrosine Kinase Inhibitors - Google Patents

Bruton Imidazopyrazine Tyrosine Kinase Inhibitors

Info

Publication number
EA201991456A1
EA201991456A1 EA201991456A EA201991456A EA201991456A1 EA 201991456 A1 EA201991456 A1 EA 201991456A1 EA 201991456 A EA201991456 A EA 201991456A EA 201991456 A EA201991456 A EA 201991456A EA 201991456 A1 EA201991456 A1 EA 201991456A1
Authority
EA
Eurasian Patent Office
Prior art keywords
imidazopyrazine
bruton
tyrosine kinase
kinase inhibitors
compounds
Prior art date
Application number
EA201991456A
Other languages
Russian (ru)
Other versions
EA037031B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/058319 external-priority patent/WO2018116259A1/en
Publication of EA201991456A1 publication Critical patent/EA201991456A1/en
Publication of EA037031B1 publication Critical patent/EA037031B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

В некоторых вариантах изобретение относится к соединениям формул (I) и (II) или их фармацевтически приемлемой соли или к фармацевтическим композициям, содержащим эти соединения, и к их применению в терапии. В частности, в некоторых вариантах данное изобретение относится к соединениям формул (I) и (II), их фармацевтическим композициям и к применению соединений и фармацевтических композиций в лечении гиперпролиферативного расстройства, воспалительного расстройства, иммунного расстройства или аутоиммунного расстройства.In some embodiments, the invention relates to compounds of formulas (I) and (II), or a pharmaceutically acceptable salt thereof, or to pharmaceutical compositions containing these compounds and their use in therapy. In particular, in some embodiments, this invention relates to compounds of formulas (I) and (II), pharmaceutical compositions thereof, and the use of the compounds and pharmaceutical compositions in the treatment of hyperproliferative disorder, inflammatory disorder, immune disorder, or autoimmune disorder.

EA201991456A 2017-10-06 2017-12-21 Imidazopyrazine inhibitors of bruton's tyrosine kinase EA037031B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762569028P 2017-10-06 2017-10-06
PCT/IB2017/058319 WO2018116259A1 (en) 2016-12-21 2017-12-21 Imidazopyrazine inhibitors of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
EA201991456A1 true EA201991456A1 (en) 2019-11-29
EA037031B1 EA037031B1 (en) 2021-01-28

Family

ID=68653623

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991456A EA037031B1 (en) 2017-10-06 2017-12-21 Imidazopyrazine inhibitors of bruton's tyrosine kinase

Country Status (1)

Country Link
EA (1) EA037031B1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514444B2 (en) * 2006-09-22 2009-04-07 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP2734523A1 (en) * 2011-07-19 2014-05-28 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
WO2015110923A2 (en) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
WO2016106623A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106627A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors

Also Published As

Publication number Publication date
EA037031B1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
SA519402217B1 (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
CY1121850T1 (en) DIARYLO MACROCYLES AS REGULATORS OF PROTEIN KINASES
EA202092590A1 (en) PYRIDAZINONES AS PARP7 INHIBITORS
EA201891229A1 (en) EIF4A-INHIBITING COMPOUNDS AND RELATED METHODS
EA201790951A1 (en) DERIVATIVES OF HYDROXYLKYL SUBSTITUTED PHENILTRIASOLE AND THEIR USE
EA201691114A1 (en) BIARRYLIC CONNECTIONS USED IN THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEPHROLOGY AND IMMUNOLOGY
EA201891268A1 (en) COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA201992350A1 (en) COMBINED MEDICINES AIMED AT PD-1, TIM-3 AND LAG-3
EA202090291A2 (en) BIPIRAZOLE DERIVATIVES AS JAK INHIBITORS
EA201892075A1 (en) COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
EA201792304A1 (en) COMBINED THERAPY FOR CANCER TREATMENT
EA201990424A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
EA201692313A1 (en) Derivatives of indolysine as inhibitors of phosphosinositide-3-kinase
EA201692470A1 (en) PHARMACEUTICAL COMBINATIONS
EA201990428A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
EA201790745A1 (en) TRICYCLIC COMPOUNDS
EA201891050A1 (en) COMPOUNDS PYRROLO, PYRAZOLO, IMIDAZOPYRIMIDINE AND PYRIDINE THAT INHIBIT MNK1 AND MNK2
EA201790870A1 (en) TRICYCLIC TROPICOMETRIC COMPOUNDS
EA201792057A1 (en) CONDENSED BICYCLIC HETEROYARIL DERIVATIVES WITH ACTIVITY OF PROHYLDROXYLASE INHIBITORS
EA201790699A1 (en) STABILIZED DERIVATIVES OF ADRENOMEDULLINE AND THEIR APPLICATION
EA202090270A1 (en) NEW SUBSTITUTED Xanthine Derivatives
EA201792445A1 (en) NEW AMIDOGETEROARILOROILYL HYDRAZIDETHINES
EA201791819A1 (en) COMBINED THERAPY WITH ANTIBODY CONJUGATE AGAINST CD19 WITH MEDICINE AND VINCRISTINE
EA202090266A1 (en) MPO INHIBITORS FOR MEDICAL USE